Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab Therapy for Non-Ischemic Central Retinal Vein Occlusion

NCT01295112 is registered in ClinicalTrials.gov with Texas Retina Associates as lead sponsor.

NCT NCT01295112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01295112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab Therapy for Non-Ischemic Central Retinal Vein Occlusion
Lead sponsor
Texas Retina Associates
Phase
Phase 2/3
Overall status
Completed
Start date
May 31, 2011
Completion date
October 31, 2015
Enrollment
68 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-ischemic central retinal vein occlusion